Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Rebecca Overbury¹, Shaobo Pei ², Gopi Penmetsa ³, Brian Sauer ², Vikas Patil ², Jodi Walker ⁴, Jerry Clewell ⁴, Kevin Douglas ⁴, Daniel Clegg ⁵, Grant Cannon ⁶, Ahmad Halwani ⁷ and Jessica Walsh ⁸, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²Division of Epidemiology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Gopi K. Penmetsa, MD, Division of Rheumatology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁷Division of Hematology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁸Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…
Abstract Number: 512 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY
Meliha Kapetanovic¹, Maria Andersson ², Alan Friedman ³, Tim Shaw ³, Yanna Song ⁴, Daniel Aletaha ⁵, Maya H. Buch ⁶, Ulf Müller-Ladner ⁷ and Janet Pope ⁸, ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ²Abbvie AB, Solna, Sweden, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁵Medical University of Vienna, Vienna, Austria, ⁶University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁷Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Gießen, Hessen, Germany, ⁸Western University, London, ON, Canada
Background/Purpose: Early treatment of RA within the therapeutic window (0-3 months from symptom onset), has been associated with improved clinical outcomes and physical function. However,…
Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
pia Lois¹, Zulema Rosales Rosado ¹, Judit Font Urgelles ², Cristina Vadillo Font ¹, isabel Hernandez Rodriguez ¹, Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…
Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado¹, pia Lois ¹, Arkaitz Mucientes Ruiz ¹, Esperanza Pato Cour ¹, Dalifer Freites Nuñez ², Juan Angel Jover Jover ¹, lydia Abasolo Alcazar ¹ and Leticia León ³, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²Hospital Clínico San Carlos, MADRID, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
Abstract Number: 2376 • 2019 ACR/ARP Annual Meeting
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
Zoe Brown ¹, Robert Metcalf ², Jana Bednarz ³, Christiana Stavrou ⁴, Llewellyn Spargo ², Michael James ² and Susanna Proudman⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, Australia, ⁴University College London Hospital, London, United Kingdom, ⁵University of Adelaide, Adelaide, Australia
Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated…
Abstract Number: 107 • 2019 ACR/ARP Annual Meeting
Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium
William Murray-Brown¹, Yanxia Guo ², Mihir Wechalekar ¹, Helen Weedon ¹, Malcolm Smith ¹, Susanna Proudman ³, Navin Rao ⁴, Sunil Nagpal ⁴ and Mihir Wechalekar ¹, ¹Flinders University, Adelaide, Australia, ²Janssen Research, Spring House, ³Adelaide University, Adelaide, Australia, ⁴Janssen R&D, Spring House, PA
Background/Purpose: Programmed cell death protein 1 (PD-1) expressing T-cells are implicated in the pathogenesis of autoimmune inflammatory diseases such as rheumatoid arthritis (RA). In secondary…
Abstract Number: 1182 • 2019 ACR/ARP Annual Meeting
Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach
Yogan Kisten¹, Adrian Levitsky ¹, Hamed Rezaei ¹, Aase Hensvold ², Per Larsson ³, Erik af Klint ¹, Ronald van Vollenhoven ⁴ and Anca Catrina ⁵, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ³Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁴Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, ⁵Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Among the arsenal of available techniques for arthritis prediction and diagnosis, fluorescence optical imaging (FOI) has shown to be useful in detecting clinically manifest…
Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
isabel Hernandez Rodriguez¹, Zulema Rosales Rosado ¹, pia Lois ¹, Cristina Lajas ¹, Judit Font Urgelles ², Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…
Abstract Number: 179 • 2019 ACR/ARP Annual Meeting
The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry
Sofia Pazmino ¹, Veerle Stouten ¹, Patrick Verschueren ², Pavlos Mamouris ¹, Rene Westhovens ³, Kurt De Vlam ², Delphine Bertrand ¹, Kristien Van der Elst ², Bert Vaes ¹ and Diederik De Cock¹, ¹KU Leuven, Leuven, Belgium, ²University Hospital Leuven, Leuven, Belgium, ³University Hospitals, Leuven, Belgium
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PSA) and spondyloarthritis (SPA) are the most common inflammatory rheumatic diseases, associated with a high burden of comorbidities and…
Abstract Number: 1205 • 2019 ACR/ARP Annual Meeting
Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Susan J. Bartlett ², Marie-France Valois ³, Louis Bessette ⁴, Gilles Boire ⁵, Glen Hazlewood ⁶, Carol Hitchon ⁷, Edward Keystone ⁸, Janet Pope ⁹, Carter Thorne ¹⁰, Diane Tin ¹¹, Vivian Bykerk ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹University of Toronto, Montreal, Canada, ²McGill University, Montreal, QC, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec City, QC, Canada, ⁵Sherbrooke University, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁹Western University, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, Canada, ¹²Hospital for Special Surgery, New York City, NY, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Early RA diagnosis and initiation of DMARDs following a treat-to -target approach is recommended to optimize remission outcomes. Several RA disease activity indices are…
Abstract Number: 2395 • 2019 ACR/ARP Annual Meeting
DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment
Theodore Pincus¹, jaquelin Chua ², Joel Block ² and Isabel Castrejon ², ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, chicago, IL
Background/Purpose: A study of patients with RA at their first visit to an academic rheumatology site indicated an unexpected observation that 75% of patients had…
Abstract Number: 198 • 2019 ACR/ARP Annual Meeting
Assessing Care Quality in Rheumatology Services
Mark Yates¹, Sam Norton ¹, Alexander MacGregor ², Katie Bechman ³, Sanketh Rampes ³ and James Galloway ⁴, ¹Kings College London, London, ²University of East Anglia, Norwich, United Kingdom, ³King's College London, London, United Kingdom, ⁴Kings College London, London, United Kingdom
Background/Purpose: There is high-quality evidence that prompt diagnosis and treatment have beneficial impact on outcomes in RA. Current guidelines from both North America and Europe…
Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk ², Orit Schieir ³, Marie-France Valois ⁴, Susan J. Bartlett ⁵, Louis Bessette ⁶, Gilles Boire ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Carter Thorne ¹¹, Diane Tin ¹² and Glen Hazlewood ¹, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York City, NY, ³University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ⁴McGill University, Montreal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷Sherbrooke University, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Canada
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
Abstract Number: 2818 • 2019 ACR/ARP Annual Meeting
Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis
Virginia Muir ¹, Cliff Rims ¹, Kevin Deane ², Jeffrey Carlin ³, Sylvia Posso ¹, Sunil Nagpal ⁴, Navin Rao ⁴, Frédéric Baribaud ⁵, George Vratsanos ⁶, William Robinson ⁷, Gary Firestein ⁸, V. Michael Holers ⁹, Peter Linsley ¹, Eddie James¹ and Jane Buckner ¹, ¹Benaroya Research Institute, Seattle, WA, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³Virginia Mason Medical Center, Seattle, WA, ⁴Janssen R&D, Spring House, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶JNJ, Raritan, NJ, ⁷Stanford University, Palo Alto, CA, ⁸University of California, San Diego, San Diego, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
Abstract Number: 451 • 2019 ACR/ARP Annual Meeting
Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores
Vivian P. Bykerk¹, Orit Schieir ², Marie-France Valois ³, Gilles Boire ⁴, Glen Hazlewood ⁵, Louis Bessette ⁶, Carol Hitchon ⁷, Diane Tin ⁸, Carter Thorne ⁹, Edward Keystone ¹⁰, Janet Pope ¹¹, Susan J. Bartlett ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹Hospital for Special Surgery, New York, NY, ²University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ³McGill University, Montreal, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Southlake Regional Health Centre, Newmarket, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹¹Western University, London, ON, Canada, ¹²McGill University, Montreal, QC, Canada, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Persisting pain (NRS ≥4,) (PP) and non-articular pain (NAP), reduces quality of life for patients with RA. NAP is often attributed to fibromyalgia (FM),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.